Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gantacurium is an investigational, ultra-short acting, non-depolarizing neuromuscular blocking agent of the asymmetric mixed-onium chlorofumarate class. It is a single-isomer isoquinolinium diester of chlorofumaric acid and represents a third-generation tetrahydroisoquinolinium (THIQ) neuromuscular blocker. Gantacurium acts as an antagonist at the neuronal acetylcholine receptor subunit alpha-3, thereby inhibiting neuromuscular transmission and inducing skeletal muscle relaxation. Its onset is rapid and its duration of action is comparable to succinylcholine but without the latter’s side effects. Gantacurium undergoes unique metabolism via rapid cysteine adduction (chemo-inactivation) and slower pH-sensitive hydrolysis, allowing for spontaneous or l-cysteine-induced reversal of blockade[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gantacurium.